Fig. 5
From: Allosteric inhibition of CRISPR-Cas9 by bacteriophage-derived peptides
Inhibition of the genome-editing activity of SpCas9 in human cells by inoviridae phage G8PPD. a Flowchart showing experimental design. b Comparison of SpCas9-inhibiting activities of phage peptides and Acrs in HEK293 cells. c G8PPD inhibits the genome-editing activity of SpCas9 across different genes in K562. d The effects of G8PPD co-transfection and pre-incubation on the genome-editing activity of CRISPR-Cas9. e Density plot showing the NGS analyses of the distribution of mutation rates along the edited genomic sites of AAVS1 in K562 cells. The results of two biological replicates are individually shown. f Inhibition of the in vitro DNA cleavage activity of SpCas9 by inoviridae G8PPD. DMSO of 0.1% is included as a solvent control. g Inhibition of SpCas9 activity in K562 cells by inoviridae G8PPD. The results are shown as mean ± SD (n = 3). Significant difference between test groups and mock is determined by one-way ANOVA with Dunnett’s multiple comparisons test. The adjusted P values are indicated